Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and differentiation. Evidence demonstrating the expression of BT...

Full description

Bibliographic Details

Published in:	Molecules
Main Authors:	Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Anna Krupa, Dariusz Pawlak
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Subjects:	Bruton’s tyrosine kinase inhibitors Bruton’s tyrosine kinase cancer solid tumor autoimmune disease
Online Access:	https://www.mdpi.com/1420-3049/28/5/2400